Physician profile
Sami Nimer Malek
NPI 1831275791
$49,469.74
in general payments reported to CMS, 2019-2025
11 companies · $2,460 in 2025
The $2,460 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $13K · 2021: $6,515 · 2022: $4,415 · 2023: $8,305 · 2024: $3,449 · 2025: $2,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,089.00 |
| Food and Beverage | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $21,077.35 | 2020-2025 | Calquence |
| Pharmacyclics LLC, An Abbvie Company | $6,273.64 | 2019-2020 | |
| Verastem, INC. | $5,344.75 | 2019 | |
| Beigene USA, INC. | $3,825.00 | 2021-2023 | Brukinsa |
| Genzyme Corporation | $3,449.00 | 2024 | |
| Janssen Scientific Affairs, LLC | $2,885.00 | 2019-2023 | Imbruvica |
| Beigene, LTD. | $1,950.00 | 2021 | |
| Abbvie INC. | $1,650.00 | 2021-2022 | |
| Janssen Biotech, INC. | $1,515.00 | 2021 | |
| Adaptive Biotechnologies Corporation | $1,500.00 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sami Malek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.